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ECMNeuraminidase 1 (NEU1) regulates the catabolism of sialoglycoconjugates in lysosomes. Congenital NEU1
deﬁciency in children is the basis of sialidosis, a severe neurosomatic disorder in which patients experience a
broad spectrum of clinical manifestations varying in the age of onset and severity. Osteoskeletal deformities
and muscle hypotonia have been described in patients with sialidosis. Here we present the ﬁrst
comprehensive analysis of the skeletal muscle pathology associated with loss of Neu1 function in mice. In
this animal model, skeletal muscles showed an expansion of the epimysial and perimysial spaces, associated
with proliferation of ﬁbroblast-like cells and abnormal deposition of collagens. Muscle ﬁbers located adjacent
to the expanded connective tissue underwent extensive invagination of their sarcolemma, which resulted in
the inﬁltration of the ﬁbers by ﬁbroblast-like cells and extracellular matrix, and in their progressive cytosolic
fragmentation. Both the expanded connective tissue and the juxtaposed inﬁltrated muscle ﬁbers were
strongly positive for lysosomal markers and displayed increased proteolytic activity of lysosomal cathepsins
and metalloproteinases. These combined features could lead to abnormal remodeling of the extracellular
matrix that could be responsible for sarcolemmal invagination and progressive muscle ﬁber degeneration,
ultimately resulting in an overt atrophic phenotype. This unique pattern of muscle damage, which has never
been described in any myopathy, might explain the neuromuscular manifestations reported in patients with
the type II severe form of sialidosis. More broadly, these ﬁndings point to a potential role of NEU1 in cell
proliferation and extracellular matrix remodeling.tective protein/cathepsin A;
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Compartmentalized degradation of sialoglycoconjugates is ini-
tiated in lysosomes by the glycosidase N-acetyl-α-neuraminidase-1
(NEU1), a pivotal enzyme required for the removal of terminal
sialic acid residues [1]. NEU1 is transported to lysosomes and
activated therein by associating with the serine carboxypeptidase
protective protein/cathepsin A (PPCA) [2]. NEU1 is a component of
a multiprotein complex containing PPCA, β-galactosidase, and N-acetylgalactosamine-6-sulfate sulfatase. Two genetically distinct
lysosomal storage diseases are associated with NEU1 deﬁciency:
sialidosis, which results from structural mutations at the NEU1 locus
on chromosome 6p21 [3], and galactosialidosis, which is caused by a
primary defect of PPCA, leading to secondary deﬁciencies of NEU1 and
β-galactosidase [4]. Patients with sialidosis experience a broad
spectrum of clinical manifestations, varying in the timing of onset and
severity of the symptoms and mostly correlating with the levels of
residual enzyme activity [5]. Type I sialidosis, the attenuated formof the
disease, occurs during the second decade of life and results in
progressive loss of vision associated with nystagmus, ataxia, and
grand-mal seizures but not dysmorphic features [3]. Type II sialidosis,
the severe form of the disease, is characterized by hydrops foetalis and
neonatal ascites, the presence of abnormal somatic features, and severe
neurologic involvement. A subset of patients with sialidosis presents
with symptoms of profound muscle dysfunction, including muscle
hypotonia, atrophy, and osteoskeletal deformities [5]. However, a
detailed characterization of the muscle involvement in these patients
has never been reported.
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pathologicmanifestations seen in patientswith the early-onset forms of
sialidosis, including growth retardation, splenomegaly, severe neuro-
logic deterioration, and premature death [6]. Spleen enlargement in
these mice coincides with the time-dependent occurrence of extra-
medullaryhematopoiesis.Our previous studies of themolecular bases of
this phenotype identiﬁed Neu1 as a negative regulator of lysosomal
exocytosis [7]. The latter is a Ca2+-dependent process that entails the
recruitment/docking of lysosomes to the plasma membrane (PM), the
fusion of the lysosomal membrane with the PM, and the release of
lysosomal contents into the extracellular matrix (ECM) [8]. We found
that the lysosomal-associated membrane protein-1 (Lamp-1), which
has been implicated in the recruitment/docking of lysosomes to the PM,
is a substrate of Neu1. In the absence of Neu1, oversialylated Lamp-1 has
a longer half-life, and this increases the number of lysosomes poised to
dock at the PM and to engage in lysosomal exocytosis [7]. The down-
stream effect is the enhanced release of catalytically active proteases
and glycosidases extracellularly, a phenomenon that affects the
processing of cell surface proteins and ECM components [7]. In the
ﬁbroblasts of patients with sialidosis who have different clinical
phenotypes, we demonstrated an inverse correlation between the
levels of the residual NEU1 activity and the increase in lysosomal
exocytosis. Given the ubiquitous tissue distribution of this lysosomal
enzyme, it is conceivable that the process of lysosomal exocytosis in
absence of Neu1 activity is deregulated in other tissues and underlie
many of the pathologic manifestations characteristic of this disease,
albeit the downstream effects of this process may be cell type-speciﬁc.
In addition to their role in the intralysosomal catabolismof sialylated
macromolecules, NEU1 and PPCA are found at the cell surface together
with the elastin-binding protein as part of the elastin receptor protein
complex [9,10]. It has been postulated that within this complex NEU1
participates in the regulation and assembly of the elastic ﬁbers [9,11].
Recently, Starcher et al. [12] demonstrated that elasticﬁberdeposition is
altered in the aorta and lung of Neu1-null mice and that the impaired
extracellular assembly of the elastic ﬁbers causes this effect. In skeletal
muscle, the interplay between the ECM and individual muscle ﬁbers is
crucial for the normal function and integrity of this tissue. In addition to
providingmechanical support, the ECMand, in particular, the basement
membrane/basal lamina function as a scaffold during muscle regener-
ation. Components of these structures and the muscle ﬁbers, such as
collagens, laminins, integrins, and dystroglycans, represent bona ﬁde
signaling molecules that play key roles in muscle development,
maintenance, and regeneration. Disturbing any of these components
may adversely affect muscle strength and integrity and result inmuscle
disease [13–15]. The concept that NEU1 may directly or indirectly
inﬂuence the behavior of extracellular components by altering the sialic
acid content of intracellular and extracellular substrates could be a
common determinant of many of the systemic abnormalities charac-
teristic of sialidosis.
Here we show that in Neu1−/− mice, muscle ﬁbers undergo
progressive disruption associated with profound alterations of ECM
components and inﬁltration by connective tissue. Many of these
abnormalities can be attributed to excessive expansion of perimysial
and endomysial connective tissue, coupled to increased proliferation
of ﬁbroblast-like cells, abnormal deposition of collagen ﬁbers, and
enhanced proteolytic activity in the ECM. These ﬁndings explain, in
part, the neuromuscular signs and symptoms described in patients
with sialidosis and indicate a primary role of NEU1 in the pathogenesis
of muscle diseases.
2. Materials and methods
2.1. Animals
Neu1−/− and wild-type (WT) mice (FVB/NJ background), aged
15 days to 7 months, were included in this study. The Neu1−/− micewere previously generated in our laboratory by targeted disruption in
the Neu1 locus [6]. Animals were housed in a fully AAALAC-accredited
animal facility with controlled temperature (22 °C), humidity, and
lighting (alternating 12-hour light–dark cycles). Food and water were
provided ad libitum. All procedures in mice were performed according
to animal protocols approved by our Institutional Animal Care and Use
Committee and NIH guidelines.
2.2. Histology
The gastrocnemius, tibialis anterior, quadriceps, and diaphragm
were excised for analysis. The gastrocnemius muscles were weighed
for comparison between Neu1−/− [1–2 months (n=6), 3–4 months
(n=5), and 5–6 months (n=5)] and WT [1–2 months (n=8), 3–
4 months (n=4), and 5–6 months (n=5)] mice. The muscle tissues
were dissected, frozen immediately in isopentane cooled in liquid
nitrogen, and stored at−80 °C until processed for histologic analysis.
Fragments of muscle tissues were also ﬁxed in 4% paraformaldehyde
(PFA) for immunohistochemical analysis and 4% glutaraldehyde for
electronmicroscopy. Longitudinal or transverse sections (8 µm) of the
frozen muscles were cut on a cryostat (Leica CM3050). The sections
were stained with hematoxylin and eosin (H&E) for overall mor-
phologic assessment. Cross-sectional areas of gastrocnemius muscles
from three Neu1−/−mice and three matching controls (5–6 months)
stained with H&E were measured by tracing each individual myoﬁber
by using the ImageJ software (NIH Software). At least 200 ﬁbers
were measured per animal in three different ﬁelds of gastrocnemius
muscles.
2.3. Immunohistochemistry
The indirect immunoﬂuorescence method was done for the
analyses of the following proteins: transcription factor 4 (TCF4;
rabbit monoclonal, Cell Signalling #2565, 1:100), dystrophin (mouse
monoclonal, Sigma D8168, 1:400), β-dystroglycan (mouse monoclo-
nal, Abcam ab49515, 1:200), and laminin (rabbit polyclonal, Sigma
L9393, 1:200). Frozen sections were blocked with blocking solution
containing 2% BSA and 10% normal serum in PBS for 30 min. Sections
used for monoclonal antibodies were incubated with AfﬁniPure Fab
Fragment Goat Anti-Mouse IgG (H+L) (Jackson ImmunoResearch) in
PBS for 1 hour. Sections were incubated with primary antibodies
diluted in blocking solution for at least 1 hour at room temperature or
overnight at 4 °C, washed three times for 10 min with PBS, and
blocked with blocking solution for 10 min. The sections were
incubated with Alexa-488 or Cy3 (anti-mouse or anti-rabbit), with
or without 488-phalloidin for 40 min, washed in PBS (ﬁve times for
5 min), and mounted with Vectashield mounting medium/DAPI
(Vector, H1000). As an internal control, samples were incubated
with only the secondary antibody. The slides were examined under a
ﬂuorescent microscope (Olympus BX50, NY, USA) or confocal micro-
scope (Zeiss LSM510 Meta, NY, USA, or Nikon C1Si, NY, USA).
The immunoperoxidase procedure was done to analyze the levels
of collagen IV (rabbit polyclonal, Abcam ab13966, 1:400), collagen VI
(rabbit polyclonal, Santa Cruz sc-20649, 1:100), reticulin (rat mono-
clonal, Acris BM4018, 1:100), tenascin (rabbit polyclonal, Chemicon
International AB19013, 1:500), cathepsin B (rabbit polyclonal, Upstate
#06-480, 1:100), Lamp-1 (rat polyclonal, BD Pharmingen #553793,
1:100), Lamp-2 (rabbit polyclonal, Zymed #51-2200, 1:200), pax7
(mouse monoclonal, Developmental Studies Hybridoma Bank), and
proliferating cell nuclear antigen (PCNA; rabbit polyclonal, Abcam
ab15497, 1:200). Slides were washed in PBS and incubated for 30 min
with blocking solution (1% BSA, 0.5% Tween-20, and 10% normal goat
serum in PBS). Subsequently, the primary antibody was diluted in
blocking solution, and slides were incubated overnight at 4 °C. The
sections were then rinsed in PBS, incubated with biotinylated anti-
mouse or anti-rabbit secondary antibodies for 60 min, rinsed in PBS,
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for 60 min. The endogenous peroxidase activity was quenched with
0.3% hydrogen peroxide in PBS for 30 min. The slides were rinsed in
PBS and incubated with 3,3′-diaminobenzidine substrate solution
(DAB; Invitrogen) for 2 to 4 min. The reaction was stopped in distilled
water, and the slides were counterstained with H&E and examined on
an Olympus microscope (Olympus BX50, NY, USA).
2.4. Western blot analysis
For western blot analysis, muscle fragments were homogenized
with ﬁve volumes of RIPA buffer (10% SDS, 70 mmol/L Tris–HCl (pH
6.7), 10 mmol/L EDTA, and 5% β-mercaptoethanol) with phosphatase
and protease inhibitor cocktails using a Dounce homogenizer. The
homogenates were centrifuged at 13,000×g for 5 min at 4 °C, and the
supernatants were transferred into new microtubes. The protein
concentration was determined by optical density (OD=595) using
BSA solution; 25 µg Neu1−/− or Neu1+/+ total protein underwent
electrophoresis on SDS–PAGE gel (4%–12%). The gelswerewet-blotted
overnight at 4 °C against PVDF membranes. The membranes were
blocked in TBS–Tween-20 containing 5% milk for 60 min and probed
with primary antibody diluted in blocking solution overnight at 4 °C.
The membranes were washed with TBS–Tween-20, incubated with
HRP-conjugated secondary antibodies for 1 hour, developed by using
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo
Scientiﬁc, Rockford, IL, USA). The antibodies used were as follows:
anti-Lamp-1 (rat polyclonal, BD Pharmingen #553793, 1:500), anti-
Lamp-2a and anti-Lamp-2b (gifts from Dr. Ana Maria Cuervo), anti–
cathepsin B (rabbit polyclonal, Upstate #06-480, 1:2000), and anti-
GAPDH (rabbit polyclonal, Chemicon International MAB374, 1:500).
2.5. Zymography
Gastrocnemius muscle from Neu1−/− and WT mice were
homogenized in ﬁve volumes of PBS using a Dounce homogenizer
and pelleted to remove nonsolubilized components. Nonreducing
sample buffer (62.5 mM Tris–HCl, pH 6.8, 25% glycerol, 4% SDS, and
0.01% bromophenol blue) was added to increasing concentrations of
both muscle lysates that were run on a 7.5% SDS–PAGE gel containing
1 mg/ml gelatin. The gel was incubatedwith renaturation buffer (2.5%
Triton X-100) for 30 min and development buffer (50 mM Tris–HCl,
pH 7.5, 200 mM NaCl, 5 mM CaCl2, 0.02% Brij-35) overnight at 37 °C
with one change of buffer after 30 min. Bands were visualized as clear
zones following staining with R250 Coomassie blue.
2.6. In situ zymography
In situ zymography was used to detect and localize net gelatino-
lytic and collagenolytic activity in gastrocnemius muscle sections of
Neu1−/− and WT mice. Cryosections (10 µm) of muscle fragments
were air-dried and overlaid with a solution containing 50 mM Tris–
HCl, 5 mM CaCl2, 0.2 mM sodium azide, and 50 µg/ml ﬂuorescence-
labeled dye-quenched gelatin or dye-quenched collagen type I
(Molecular Probes, Eugene, OR) and incubated overnight at 37 °C.
Omission of the substrates served as a negative control. After three
washes with PBS, slides were mounted in Vectashield mounting
medium/DAPI (Vector, H1000).
For the analysis of collagen IV breakdown, the cryosections were
overlaid with a buffer containing Collagen IV Oregon Green-488
(Molecular Probes), incubated for 2 hours at 37 °C in a humidifying
chamber, and ﬁxed with 4% PFA. The slides were washed and
mounted with Vectashield mounting medium/DAPI (Vector, H1000).
As a control, the same experiment was performed using EDTA or
omitting the substrate. The slides were examined under a ﬂuorescent
microscope (Olympus BX50) or confocal microscope (Zeiss LSM510
Meta).2.7. Electron microscopy and semithin sectioning
For the electron microscopic studies, isolated tibialis and gastroc-
nemius muscles from Neu1−/− and WT mice were ﬁxed in 4%
glutaraldehyde, postﬁxed in 1% OsO4, and en bloc stained with 1%
uranyl acetate. After standard dehydration, samples were inﬁltrated
and embedded in Spurr low-viscosity resin (Electron Microscopy
Sciences) and polymerized at 60 °C for 18 hours. Semithin sections
(0.5 µm) were stained with 1% toluidine blue. Sections (600–900 Å)
were stained in grids with Reynolds lead citrate and uranyl acetate.
The grids were analyzed in the Jeol “JEM-1200 EX-II”microscope with
an AMT CCD camera.2.8. Semiquantitative RT–PCR
Total RNAwas isolated from gastrocnemiusmuscles fromNeu1−/−
and WT mice (4–6 months; n=3) using TRIZOL reagent (Invitrogen,
Carlsbad, CA). The quantity of RNA was measured, and its purity was
conﬁrmed by spectroscopy. RNAwas treatedwith ampliﬁcation-grade
DNAse I (Applied Biosystems/Ambion, Foster City, CA) to remove
genomic DNA as per the manufacturer's instructions. First-strand
complementaryDNAwas producedusing 1 µg of total RNAwith aﬁrst-
strand cDNA Superscript II Reverse Transcriptase Kit (Invitrogen,
Carlsbad, CA). cDNA was used as a template for the PCR in a 25-µl
reaction volume including 2 µM of each primer, dNTPs (400 µM each),
2 mM MgCl2, 2.5 µl Taq polymerase buffer (10×), and 0.625 U Taq
polymerase (Invitrogen), for 29 cycles. Speciﬁc primers used are
summarized in Suppl. Table 1. Primer sequences for ampliﬁcations
were designed based on published cDNA sequences. The PCR products
were resolved on a 2% agarose gel containing 0.005% ethidium
bromide and visualized with ultraviolet light. The intensity of the
bands was calculated using ImageJ software (NIH) and normalized
against 18S or β-actin expression.2.9. Cathepsin B deglycosylation assay
Fibroblasts were collected fromNeu1−/− andWTmuscle fragments,
and equal numbers of cells were seeded in 35-mm plates and
maintained in complete DMEM medium. At 100% conﬂuence, the cells
were harvested and lysed with RIPA buffer on ice for 30 min. The
homogenates were centrifuged at 13,000×g for 5 min at 4 °C, and the
supernatants were transferred into newmicrotubes. Enzymatic protein
deglycosylation was performed using an enzymatic deglycosylation kit
(Prozyme, Hayward, CA) as per themanufacturer's instructions. In brief,
60 µg of lysate from Neu1−/− or Neu1+/+ ﬁbroblasts was incubated
with N-glycanase, O-glycanase, sialidase I, or a combination of all three
enzymes for 3 hours at 37 °C. Samples were run on a Bis–Tris gradient
gel (4%–12%), blotted against a PVDF membrane, and probed with a
rabbit anti-cathepsin B antibody overnight at 4 °C.2.10. Fibroblast exocytosis assay
An equivalent number of ﬁbroblasts from Neu1−/− and WT mice
were seeded in triplicate in 6-well plates. At 100% conﬂuence, the
medium (DMEM, pen-strep, GlutaMAXTM, and 10% FBS) was replaced
with 1 ml DMEM containing 1% BSA (wt./vol.) with or without
calcimycin (10 µM) and incubated for 2 hours at 37 °C. The medium
was collected and centrifuged to pellet the dead cells. The supernatant
was stored at −80 °C. Enzyme activities were measured with the
appropriate ﬂuorometric or colorimetric substrates as previously de-
scribed [7]. Cathepsins B and L were assayed using InnoZyme activity
assay kits (EMD Biosciences, Madison, WI) as per the manufacturer's
instructions.
Fig. 1. Growth retardation and progressive skeletal muscle atrophy in Neu1−/− mice.
(A) A comparison of a representative 4-month-old male Neu1−/− mouse (KO) and its
WT littermate. (B) Atrophic gastrocnemius muscles of KO and WT mice. (C) The ratios
of gastrocnemius muscle weight per body weight at different ages shows signiﬁcant,
progressive wasting of KO muscles (blue; 1–2 months [n=6], 3–4 months [n=5], and
5–6 months [n=5]) compared to WT tissues (red; 1–2 months [n=8], 3–4 months
[n=4], and 5–6 months [n=5]) (⁎⁎pb0.01, ⁎⁎⁎pb0.001; two-way ANOVA). (D) The
average ﬁber cross-sectional area of KO gastrocnemius muscle (1.54 mm2, n=3; three
ﬁelds each) was signiﬁcantly less than that of their age-matched controls (2.70 mm2,
n=3; three ﬁelds each) (⁎⁎⁎pb0.001; Student's t test).
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3.1. Increased number of ﬁbroblast-like cells and expansion of ECM
components in Neu1−/− skeletal muscle
Like children with the severe form of sialidosis (type II), Neu1−/−
mice have growth delay and remain smaller than their WT littermates
throughout their life span (approximately 6–8 months) (Fig. 1A).
Gross examination of the limb muscles revealed overt muscle atrophy
(Fig. 1B) associated with progressive motor impairment. To deter-
mine the extent of the atrophic phenotype, we compared the weight
of the gastrocnemius muscles isolated from Neu1−/− and WT mice of
different ages. The muscle/body weight ratio (mg/g) of Neu1-
deﬁcient mice was signiﬁcantly smaller than that of controls, and
the disparity between the two phenotypes increased with age
(Fig. 1C). In addition, the cross-sectional area of the Neu1−/−
gastrocnemius muscle was smaller than that of WT mice (Fig. 1D),
conﬁrming the occurrence of an atrophic phenotype.
Histologic examination of hematoxylin/eosin stained sections of
skeletal muscle fascicles from 20 Neu1−/− mice (aged 2 weeks to
7 months) identiﬁed extended areas of muscle connective tissue,
preferentially in the epimysial and perimysial spaces, with increased
cellularity and greatly augmented (ECM) compared to the WT
sections (Figs. 2A and B). These severe abnormalities were detected
throughout the length of the muscle, including the myotendinous
junctions and tendons (Figs. 2D, F, and H) and were not observed in
the WT littler mate control (Figs. 2C, E, and G). Although intrusion
of the ECM into the cytosol of the muscle ﬁbers and thickening and
digit-form appearance of the sarcolemma are normal characteristics
of myotendinous junctions, in Neu1−/− mice, these features were
abnormally and ectopically present throughout the muscle and were
accompanied by increased cellularity and extensive muscle ﬁber
disruption (Figs. 2D and F). In young animals, the central areas of the
fascicles were largely spared and maintained an overall normal
appearance and organization; however, in mice older than 5 months,
the endomysial space was also expanded with increased cellularity.
Different muscles, i.e., gastrocnemius, quadriceps, tibialis anterior,
triceps brachialis, and diaphragm showed similar histologic altera-
tions, indicatinga generalized skeletalmuscle involvement inNeu1−/−
mice.
To characterize better the hypercellularity observed in the
abnormally expanded connective tissue, we ﬁrst immunostained
Neu1−/− muscle for immune cell markers (i.e., CD3, CD11b, and Ly-
6G) (Fig. S1A). No positive reaction was detected in any muscle
examined, indicating that immune cells did not contribute to the
increased cellularity in the affected areas. Similarly, staining with the
satellite cells-speciﬁc marker Pax 7 did not identify an increased
number of satellite cells in the affected muscle compared to the WT
muscle (Fig. S1B). In contrast, a strong positive staining was obtained
with an antibody against transcription factor 4, the earliest marker of
developing muscle connective tissue [16], suggesting that these cells
represent a population of ﬁbroblast-like cells (Fig. 3A). Moreover,
most of the ﬁbroblast-like cells stained positive for proliferating cell
nuclear antigen, a DNA-binding protein that is expressed during the S
phase of the cell cycle (Fig. 3B), which indicates that the cells were
actively dividing.
3.2. ECM components and proteolytic activity are increased in Neu1−/−
skeletal muscle
Immunostaining of Neu1−/− muscle with antibodies against
collagens III (reticulin), IV, and VI demonstrated prominent positivity
in the inﬁltrated areas adjacent to the muscle fascicles (Fig. 4A). In
addition, immunostaining for tenascin, which is highly expressed in the
myotendinous junctions, showed aberrant distribution of this protein
with large tenascin-positive areas extending into the endomysium
Fig. 2. H&E staining of transverse sections of Neu1−/− (KO) gastrocnemius muscle. This analysis shows the presence of large areas of connective tissue inﬁltrates and increased
number of cells in (B) the epimysium and perimysium spaces, (D and F) myotendinous junction, and (H) tendon. Normal histology of (A) gastrocnemius muscle, (C and E)
myotendinous junction, and (G) tendon from a WT mouse.
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strated increased levels of mRNA for collagens I, IV, and VI and laminin-
α2 (Fig. 4B). These results demonstrated an overall increase in the
synthesis of ECMcomponents in themuscle connective tissue ofNeu1−/−
mice.
Homeostasis of the ECM depends on the correct balance between
synthesis and degradation of its components. Considering the ob-
served accumulation of different types of collagens in the Neu1−/−
ECM, we tested whether this phenotypic alteration was accompanied
by deregulated activity of speciﬁc matrix metalloproteinases (MMPs)
that are responsible for the remodeling and turnover of the ECM.
Using gelatin zymography of total lysates of quadriceps muscle from
Neu1−/− and WT mice, we detected a dramatic overexpression and
activation of MMP2 and MMP9 (Fig. 5A). These two gelatinases
normally degrade collagen IV and other collagens (V, VII, and X) aswell as basal lamina components, such as ﬁbronectin and laminin. To
assess the speciﬁc localization where the aberrantly increased MMP
activity occurred, we performed gelatin and collagen IV in situ
zymography on the gastrocnemius, tibialis anterior, and quadriceps
muscle tissues from Neu1−/− and WT mice. A substantial increase in
the gelatinolytic and collagenolytic activity of MMPs was seen
predominantly within the connective tissue inﬁltrates (Fig. 5B) and,
most notably, within the muscle ﬁbers adjacent to the expanded
connective tissue (Fig. 5B, right panels).
We next tested whether the increased activity of MMPs was
paralleled by an up-regulation of their corresponding mRNAs.
Semiquantitative RT–PCR showed a signiﬁcant increase in MMP2
and MMP9 mRNA levels (Fig. 5C), together with massive accumula-
tion of ECM components. Catalytic activation of MMPs in cells in-
ﬁltrating the ECM occurs at the membrane and requires the activity of
Fig. 3. Confocal analysis of sections from Neu1−/− (KO) and WT gastrocnemius muscle. (A) Images show that most cells located at the inﬁltrated connective tissue and within the
adjacent muscle ﬁbers are transcription factor-4-positive (phalloidin, top panels shown in green; transcription factor-4, middle panels shown in red; bottom panels merge and DAPI
shown in blue). (B) Immunoperoxidase staining of similar segments revealed that the cells are also proliferating cell nuclear antigen-positive (brown).
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metalloproteinases 1 and 2 (TIMP1 and TIMP2). Indeed, we observed
that the mRNAs for these proteins were also upregulated (Fig. 5C).
Together, these results suggest that the profound alterations that
occur in the perimysium and epimysium of Neu1−/− muscle as a
consequence of Neu1 deﬁciency could have a deleterious effect on the
juxtaposed myoﬁbers.
3.3. Neu1−/− muscle ﬁbers are inﬁltrated by ﬁbroblast-like cells and
ECM components at the epimysial and perimysial sites and undergo
progressive degeneration
Analyses of toluidine blue–stained semithin sections of Neu1−/−
muscle identiﬁed additional morphologic alterations present in theFig. 4. ECMcomponents accumulate inNeu1−/− (KO)gastrocnemiusmuscle. (A) Immunohistoch
mark theKOperimysial region. (B) Semiquantitative RT–PCRof total RNA fromKOandWTgastro
IV (n=6), VI (n=3), and laminin-α2 (Lama2; n=3)) in the KO muscle (⁎pb0.05, ⁎⁎pb0.01, Sexpanded epimysial and perimysial connective tissues and the
adjacent muscle ﬁbers (Fig. 6). Most of the proliferating ﬁbroblast-
like cells had a heavily vacuolated appearance due to the presence of
numerous enlarged lysosomes in their cytoplasm (Fig. 6A), a feature
that is diagnostic of a lysosomal storage disease. At the site of the
expanded connective tissue, the muscle ﬁbers showed numerous
invaginations of the sarcolemma and inﬁltration of the ﬁbers by
ﬁbroblast-like cells and ECM components (Fig. 6B). In longitudinal
sections, these invaginations or grooves extended the length of the
myoﬁbers (Figs. 6B and C) and were recognized in transverse sections
as large vacuoles containing vacuolated cells and ECM material
(Fig. 6D). As the disease progressed, inﬁltrated myoﬁbers underwent
complete cytosolic fragmentation, which was accompanied by
gradual disruption of their cytoarchitecture (Figs. 6E and F).emical analysis showed that collagen IV,VI, collagen III (reticulin), and tenascinprominently
cnemiusmuscles demonstrated a signiﬁcant increase in the expression of collagens I (n=3),
tudent's t test), indicating an overall increase on the synthesis of the ECM proteins.
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Fig. 5. Increased activity mediated by MMPs in the ECM of Neu1−/− (KO) skeletal muscle. (A) Zymography of the total lysate from KO (n=3) and WT (n=3) quadriceps muscles
showed a higher activity of MMP2 and MMP9 in the KO mice. (B) The gelatin (top middle) and collagen IV (bottom left and middle) in situ zymography revealed an increase in
gelatinolytic and collagenolytic activity in the affected areas of KO gastrocnemius muscle, respectively. Confocal images showed increased gelatinolytic activity within the inﬁltrated
muscle ﬁbers (arrows) (right panels). (C) Expression of MMPs (MMP2, n=6; MMP9, n=3), membrane-type MMPs (n=3), and their corresponding tissue MMP inhibitors, TIMP1
(n=3) and TIMP2 (n=6), mRNA was signiﬁcantly increased in the Neu1−/− gastrocnemius muscle. ⁎pb0.05, ⁎⁎pb0.01, ⁎⁎⁎pb0.001; Student's t test.
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ultrastructural level (Fig. 7). Muscle ﬁbers adjacent to the expanded
perimysial area appeared grossly damaged by the inﬁltrating connec-
tive tissue (Figs. 7A–D). Fibroblast-like cellswereﬁlledwith numerousstorage-containing lysosomes (Figs. 7A–C). The sarcolemma of the
muscle ﬁbers extended into numerous digit-form invaginations
containing ECM components (Figs. 7D, G, and H). In addition, the
sarcolemma appeared irregularly thickened (Fig. 7E). The progressive
Fig. 6. Toluidine blue–stained semithin Neu1−/− gastrocnemius muscle sections show different stages of connective tissue inﬁltration and muscle ﬁber invagination. (A) Enlarged
lysosomes (Ly) are observed in the cytosol of proliferating ﬁbroblast-like cells (arrows) at the endomysium space in a longitudinal section. (B and C) Invagination of the sarcolemma
with inﬁltration of the muscle ﬁbers by ECM components (arrows). (D) This invagination extends the length of the myoﬁber and appears as vacuole-like structures (arrow) in the
transverse view. In a more advanced stage, ECM invagination has resulted in severe fragmentation of the cytosol and complete disruption of the muscle cytoarchitecture in (E)
longitudinal and (F) transverse sections.
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the myoﬁbers (Figs. 7A and C). Individual fragments lost the normal
muscle cytoarchitecture and displayed total disorganization of the
sarcomeric apparatus and aggregation of Z lines (Fig. 7F).
In agreement with what observed at the ultrastructural level,
immunoﬂuorescent staining of Neu1−/− muscle sections with anti-
bodies against the sarcolemmal proteins β-dystroglycan and dystro-
phin and the basal lamina protein laminin clearly highlighted the
extent of fragmentation and destruction of the myoﬁbers next to the
perimysium (Fig. 8). In addition, the intensity of the ﬂuorescent signal
was greater in the affected areas than in the normal muscle ﬁbers,
suggesting intense remodeling of the sarcolemmal components prob-
ably in response to the increased proteolytic activity and ECM changes
(Fig. 8). The fact that all three markers stained the membrane of the
vacuole-like structures in these transverse sections conﬁrmed that
they resulted from invagination of the sarcolemma (Fig. 8).
We also analyzed the ﬁber composition of the gastrocnemius,
tibialis anterior, and quadriceps muscles from WT and Neu1−/−mice
using ATPase staining (data not shown) and immunoﬂuorescence for
different isoforms of myosin heavy chains, i.e., MHC-2B, MHC-2A, and
slow-MHC (data not shown). We did not detect any differences in
ﬁber-type composition between WT and Neu1−/− mice, nor did we
observe groups of atrophied ﬁbers or angulated ﬁbers. Thus, there was
no evidence of denervation in the Neu1−/− muscle.
Interestingly, the skeletal muscle alterations observed in the
Neu1−/− mice were also detected, albeit less prominently, in thePpca-null mice, which have a secondary deﬁciency of Neu1 (Fig. S2),
but were completely absent in β-gal-null mice (data not shown),
which have normal Neu1 activity. From these experiments, we
inferred that the skeletal muscle abnormalities in Neu1-null mice
and Ppca-null mice are a direct consequence of the Neu1 deﬁciency.
3.4. Regeneration and apoptosis/necrosis do not occur in the Neu1−/−
skeletal muscle
Considering the extensive muscle destruction in Neu1−/− mice,
we predicted that regenerative and necrotic processes would occur in
the affected muscle. This assumption was also justiﬁed by the
presence of central nuclei in a few ﬁbers adjacent to the most
damaged areas (Fig. S3A). Interestingly, however, there were no signs
of overt necrosis in the Neu1−/− muscle at the histopathologic level
(Fig. 2). In addition, immunoﬂuorescent staining of muscle sections
with an antibody against embryonic myosin heavy chain did not
detect de novo formation of myoﬁbers (data not shown). Finally, as
mentioned above, immunostaining for Pax7 and MyoD, both markers
of satellite cell activation, did not identify any positive cells (Fig. S1B
and data not shown), reiterating the absence of active regeneration in
the Neu1−/− muscle.
We then determined whether Neu1−/− myoﬁbers or ﬁbroblast-
like cells underwent cell death using a TUNEL assay, which labels DNA
fragments generated during apoptosis, necrosis [17], or lysosomal
digestion [18]. Less than 1% of the cells in the expanded connective
Fig. 7. Ultrastructural analysis of Neu1−/− gastrocnemius muscle. The EM images reveal ﬁbers showing the fragmentation of the cytosol, sarcolemmal changes, and disorganization
of the internal cytoarchitecture. (A–C) Cytosolic fragmentation and inﬁltration of muscle ﬁbers by ﬁbroblast-like cells (arrows) whose cytosol is ﬁlled with storage lysosomes (Ly).
(D, G, and H) Digit-like invaginations (arrows) and (E) thickening of the sarcolemma (open arrow). (F) Cytosolic fragments within an individual muscle ﬁber with disorganization of
the internal architecture and Z-line aggregates (arrows).
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even in regions outside the myotendinous junctions. These data
support the notion that theNeu1−/−muscle ﬁbers undergo a different
mechanism of degeneration not related to apoptosis.
3.5. Neu1−/− myoﬁbers maintain sarcolemmal integrity
Low-molecular weight dyes such as Evans blue strongly stain the
interstitial spaces within the connective tissue and between skeletal
muscle ﬁbers. Therefore, the presence of such dyes inside myoﬁbers is
considered a reliable indicator of sarcolemmal damage or ﬁber
degeneration [19]. After injection of Evans blue dye in Neu1−/− mice,
only themuscleﬁbers immediately adjacent to the expanded connective
tissue showed intense ﬂuorescent signal in their cytosol. This stainingwas similar to the signal detected in the connective tissue ECM, which
indicated that it was the result of invagination of the ﬁbers by ECM
components rather than increased sarcolemmal permeability (Fig. S4).
Increased serum levels ofmuscle proteins, suchas creatinekinase,which
are normally restricted to the myoﬁber cytosol, usually accompany the
disruption of myoﬁber integrity. However, the level of serum creatine
kinase measured in Neu1−/− mice was normal (not shown), further
indicating that the sarcolemmawasnot damaged inNeu1−/−myoﬁbers.
3.6. Altered pattern of expression of lysosomal markers in the ECM of
Neu1−/− skeletal muscle
We have previously shown that Neu1 activity is pivotal for the
processing of sialic acids on the structural lysosomal proteins Lamp-1
Fig. 8. Immunoﬂuorescence staining of transverse Neu1−/− (KO) gastrocnemius muscle. Sections for sarcolemmal proteins β-dystroglycan (red), dystrophin (green), and basal
laminal protein laminin (green) show intense fragmentation with destruction of the myoﬁbers next to the perimysium. The expression of these proteins is higher in the sarcolemma
of the affected muscle ﬁbers (arrows) than in WT tissue. The vacuole-like structures stained positive for dystrophin and laminin (open arrows).
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have also demonstrated that Neu1 is a negative regulator of lysosomal
exocytosis in the Neu1−/− bone marrow and cochlear marginal cells
[7,20]. We therefore investigated the contribution of these lysosomal
proteins and the process of lysosomal exocytosis to the severe muscle
and connective tissue phenotype of Neu1−/− mice. Immunohisto-
chemical analysis of the gastrocnemius muscle from Neu1−/− mice
showed strong positivity for Lamp proteins and cathepsin B in the
areas of connective tissue inﬁltration and the juxtaposed myoﬁbers,
which was absent in the WT control (Fig. 9A, middle and left panels).
Increased levels of these proteins were also seen in the endomysial
space and most importantly within the myoﬁbers (Fig. 9A, right
panels).
These results were conﬁrmed by immunoblot analyses, which
demonstrated increased amounts of Lamp-1, Lamp-2a and b, and
cathepsin B in total muscle lysates from Neu1−/− mice (Fig. 9B). In
addition, these proteins had a distinct migration pattern compared
to that in WT tissues, conﬁrming both Lamp-1 and Lamp-2 are
oversialylated in the absence of Neu1 activity [7]. The altered
migration pattern and increased amount of cathepsin B in Neu1−/−
muscle suggested that this protein was also oversialylated. This was
conﬁrmed by in vitro enzymatic removal of all N-glycanase on
cathepsin B, which released a core protein identical in molecular
weight inNeu1−/− andWTﬁbroblast lysates, indicating that cathepsin
B is a natural substrate of Neu1 (Fig. 9C).3.7. Neu1−/− ﬁbroblasts show increased exocytosis
We demonstrated previously that in skin ﬁbroblasts from patients
with type II sialidosis the levels of Lamp-1 is increased at the PM and
this is accompanied by higher extracellular activity of α-mannosidase
[7]. These ﬁndings suggest that, even in nonsecretory cells, loss of
Neu1 activity results in increased lysosomal exocytosis. In support of
this notion, we now measured higher α-mannosidase, cathepsins B
and L activities in the culture medium of ﬁbroblasts isolated from
Neu1−/− muscle (Fig. 9D), indicating that these cells undergo
excessive lysosomal exocytosis, closely reproducing the phenotypic
alterations found in human patient ﬁbroblasts.
4. Discussion
Here we describe an unusual muscle phenotype in mice deﬁcient
for the lysosomal enzyme Neu1. The abnormalities are characterized
by dramatic expansion of the epimysial and perimysial connective
tissues with increased cellularity and ECM components. These
features are accompanied by progressive inﬁltration of proliferating
ﬁbroblast-like cells and connective tissue ECM into the adjacent
muscle ﬁbers, which ultimately lead to extreme cytosolic fragmen-
tation and myoﬁber degeneration. This atypical muscle phenotype
deﬁnes a new pathogenic model for muscle diseases and explains,
in part, the neuromuscular manifestations seen in patients with
Fig. 9. Accumulation of lysosomal components in the ECM of Neu1−/− (KO) skeletal muscle. (A) Increased Lamp-1, Lamp-2, and cathepsin B protein expression in the inﬁltrated
areas and within the inﬁltrated muscle ﬁbers (white arrows) of Neu1−/− muscle. Cathepsin B protein expression was also increased in the cells located in the endomysium space
(black arrow) (bottom right panel). (B) Lamp-1, Lamp-2a, Lamp-2b, and cathepsin B protein expression was increased and showed different mobility patterns on SDS-PAGE gel of
Neu1−/− gastrocnemius muscle lysates. (C) Deglycosylation of cathepsin B by N-glycanase. (D) The activity of α-mannosidase (α-man) and cathepsins B (CB) and L (CL) in the
culture medium collected from Neu1−/− ﬁbroblasts (blue bars, n=3) was also higher than that from WT cells (red bars, n=3). ⁎pb0.05, ⁎⁎pb0.01, ⁎⁎⁎pb0.001; Student's t test.
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osteoskeletal deformities [5]. In the future, analysis of muscle biopsies
from sialidosis patients with different clinical phenotypes would
allow us to verify this hypothesis.
A primary deﬁciency of lysosomal proteins has been associated
with different forms of skeletal muscle abnormalities [21]. However,
the phenotypic features identiﬁed in Neu1-deﬁcient mice appear todiffer from those present in other lysosomal muscle diseases, which
are mostly associated with aberrant autophagic activity. For instance,
deﬁciency of the enzyme α-glucosidase in Pompe disease results in
severe cardiac failure and muscle wasting [22]. The hallmark of this
disorder is the presence of large glycogen-ﬁlled lysosomes in tissues,
but it is the accumulation of autophagic debris and autophagosome
formation that mostly contribute to muscle weakness [23]. Similarly,
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hypertrophic cardiomyopathy, myopathy, and mental retardation
[21]. Muscle biopsies from these patients have revealed increased
number of scattered intracytoplasmic vacuoles with sarcolemmal
features and autophagic appearance [21,24]. Other rare forms of
autophagicmyopathies have been described, but their primary defects
remain unknown [21].
Similarly to our Neu1-deﬁcient mice, synaptotagmin VII (SytVII)–
null mice present with extensive ﬁbrosis in the skin and skeletal
muscle. SytVII is the Ca2+ sensor component of the multiprotein
complex that promotes the fusion of the lysosomal membrane with
the PM, which is followed by the release of the lysosomal content into
the ECM [25]. In contrast to our mice that have increased lysosomal
exocytosis, SytVII-null mice have impaired lysosomal exocytosis and
PM repair, which promotes the leakage of cytosolic content into the
extracellular space. Consequently, these mice develop an inﬂamma-
tory myopathy with an antinuclear antibody response characteristic
of autoimmune disorders [26], features not detected in the Neu1-
deﬁcient mice.
The absence of an inﬂammatory response in the Neu1−/− muscle
suggests that muscle degeneration in these mice is not due to the
release of cytosolic constituents into the ECM. Only those muscle
ﬁbers juxtaposed to the expanded connective tissue showed increased
Evans blue dye signal, which is apparently caused by connective tissue
inﬁltration rather than sarcolemmal damage. Moreover, serum
creatine kinase levels, another marker of muscle ﬁber damage, were
normal in all animals tested. However, it is unknownwhether creatine
kinase levels are normal or elevated in patients with sialidosis. Finally,
we did not observe a signiﬁcant number of newly formed myoﬁbers
with centrally located nuclei or ﬁbers expressing embryonic forms of
myosin heavy chain, which would indicate activation of the satellite
cells, an event that normally occurs after muscle lesion. Together,
these observations strongly support the notion that myoﬁber
sarcolemmal damage is not a signiﬁcant event associated with the
degeneration of Neu1−/− skeletal muscle. This justiﬁes the absence of
muscle necrosis, which is the hallmark of muscular dystrophies.
To explain the muscle phenotype in Neu1−/− mice, we reason that
the loss of Neu1 activity changes the ECM environment. Impaired
processingof sialic acid on theglycansof asyetunknown targets ofNeu1
may affect the biochemical properties of the ECM. In line with this
assumption is a recent report by [27],which suggests that Neu1plays an
important role in the down-regulation of arterial smooth muscle cell
proliferation. Using neuraminidase inhibitors, these authors showed
that Neu1 activity at the PM could structurally alter the sialic acid
content of cell surface receptors, thereby decreasing the net cellular
responsiveness to their respective mitogenic ligands. Although the
mechanisms that mediate the proliferation of ﬁbroblast-like cells in
Neu1−/− muscle remain to be elucidated, the data presented here
suggest the involvement of lysosomal enzymes, in particular Neu1, in
the control of cell proliferation and ECM remodeling.
It is tempting to speculate that the enhanced proliferation and
inﬁltration of the ﬁbroblast-like cells in Neu1−/− mice share mecha-
nistic features with the same processes observed in cancer cells.
Indeed, there is evidence that cancer cells undergo alterations in
glycosylation and sialylation of cell surface molecules, which appear
to contribute to malignant transformation, thereby increasing their
metastatic potential and invasiveness [28]. These phenotypic altera-
tions are mirrored by changes in the expression pattern of endoge-
nous sialidases [29]. In particular, there seems to be an inverse
correlation between levels of NEU1 activity and the potential of tumor
cells to proliferate, migrate, and invade in in vitro assays and
xerographs [29–31]. In addition, NEU1 overexpression also results in
the down-regulation of MMPs, which are induced in cancer cells with
high metastatic potential. These proteases comprise a family of zinc-
dependent enzymes that, together with their inhibitors, the TIMPs,
are the major physiological regulators of the turnover of the ECM [32].MMPs have been implicated in the dissemination of cancer cells by
breaking down the ECM, but they are also important in creating an
environment that supports the initiation and maintenance of growth
of primary and metastatic tumors [33,34]. Interestingly, we observed
also in Neu1−/− connective tissue-inﬁltrated muscle ﬁbers a strong
up-regulation of MMPs (MMP-2 and MMP-9), both at the protein and
mRNA levels. The strong correlation between the low-expression
levels of NEU1, the remodeling of the ECM byMMPs, and the high rate
of proliferation and invasion of colon carcinoma cells, seems to be
recapitulated in the muscle connective tissue of Neu1−/− mice. The
activation of MMPs in the muscle of these mice might facilitate the
migration of ﬁbroblast-like cells and their inﬁltration into muscle
ﬁbers, quite similarly to what observed during metastatic cancer
progression.
Besides their involvement in cancer, excess production of MMPs
leads to pathology in a wide range of other tissues [35]. Increased
expression of MMPs has been reported in atrophic skeletal muscle,
muscular dystrophies, and in inﬂammatorymyopathies [36–38].Many
studies have demonstrated that a key process in the inﬁltration of
mononuclear cells and tissue destruction in inﬂammatory disorders of
the muscle may be associated with the MMP-mediated proteolytic
disruption of the ECM components, such as basement lamina and
sarcolemma [36,38]. In this respect, it is remarkable that we observed
no increase in inﬂammatory markers or cells in the connective tissue-
inﬁltrated muscles of Neu1−/− mice. Nevertheless, we have no
indication that inﬂammation is suppressed in the muscle of Neu1−/−
mice because cardiotoxin-treated, denervated muscle tissue showed
no impairment in the inﬂammatory response (data not shown).
It is noteworthy that even with the marked increase of proteolytic
activity in the ECM, components of the basement membrane (laminin,
collagen IV) and the sarcolemma (dystrophin and β-dystroglycans)
appear to accumulate inmuscle ﬁbers juxtaposed to the affected areas.
We speculate that the accumulation of these proteinsmay be part of an
adaptive mechanism to preserve the integrity of the sarcolemma,
thereby avoiding muscle necrosis and extrusion of cytosolic compo-
nents into the extracellular space. Thus, the activation of MMPs in the
ECM of Neu1−/− mice may have two opposing consequences: (i) it
appears to structurally and physiologically alter the basement
membrane and sarcolemma of myoﬁbers to facilitate the invagination
by cells and connective tissue localized in the ECM and (ii) it may
induce an adaptive mechanism to preserve the attachment between
the sarcolemma and the ECM. However, ultimately, this adaptive
mechanism is not sufﬁcient to avoid the progressive muscle ﬁber
fragmentation and degeneration observed in these mice.
In conclusion, the unique pattern of muscle ﬁber disruption/
degeneration and connective tissue expansion and proliferation
observed in this animal model of sialidosis implicates Neu1 deﬁciency
in the deregulation of cell proliferation and ECM remodeling. These
ﬁndings will help us to gain insight into the neuromuscular mani-
festations reported in patients with sialidosis.
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